Earnings before Interest, Tax, Depreciation and Amortization (EBITDA)
Based on: 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31).
A consistent and sustained upward trajectory is evident across all primary profitability metrics from 2019 through 2023. Growth is linear and positive across each reporting period, indicating strong operational scaling and a steady increase in the ability to generate cash flow before the impact of capital structure and taxation.
- EBITDA Growth Trends
- Earnings before interest, tax, depreciation and amortization experienced uninterrupted annual growth, rising from US$ 2,436 million in 2019 to US$ 3,666 million in 2023. This represents a cumulative increase of approximately 50.5% over the five-year period. The most significant year-over-year acceleration occurred between 2020 and 2021, where EBITDA grew by 18.4%.
- Operational Profitability and Non-Cash Charges
- The progression from EBITDA to EBIT reveals a steady increase in depreciation and amortization expenses. In 2019, the difference between EBITDA and EBIT was US$ 412 million, which expanded to US$ 491 million by 2023. While these non-cash charges have risen, they have done so at a slower pace than the growth of EBITDA, suggesting an improvement in operational efficiency relative to the asset base.
- Earnings Conversion and Net Income Performance
- Net income attributable to the company mirrored the overall growth trend, increasing from US$ 1,500 million in 2019 to US$ 2,344 million in 2023. The expansion of the margin between EBITDA and net income—from US$ 936 million in 2019 to US$ 1,322 million in 2023—reflects the combined impact of higher absolute interest, tax, and depreciation expenses associated with a larger scale of operations.
AI Ask an analyst for more
Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.
How can I help you?
Enterprise Value to EBITDA Ratio, Current
| Selected Financial Data (US$ in millions) | |
| Enterprise value (EV) | 80,835) |
| Earnings before interest, tax, depreciation and amortization (EBITDA) | 3,666) |
| Valuation Ratio | |
| EV/EBITDA | 22.05 |
| Benchmarks | |
| EV/EBITDA, Competitors1 | |
| AbbVie Inc. | 32.17 |
| Amgen Inc. | 16.74 |
| Bristol-Myers Squibb Co. | 10.51 |
| Danaher Corp. | 25.34 |
| Eli Lilly & Co. | 43.11 |
| Gilead Sciences Inc. | 15.52 |
| Johnson & Johnson | 16.15 |
| Merck & Co. Inc. | 13.91 |
| Pfizer Inc. | 13.27 |
| Regeneron Pharmaceuticals Inc. | 13.23 |
| Thermo Fisher Scientific Inc. | 24.28 |
| Vertex Pharmaceuticals Inc. | 25.95 |
| EV/EBITDA, Sector | |
| Pharmaceuticals, Biotechnology & Life Sciences | 31.41 |
| EV/EBITDA, Industry | |
| Health Care | 25.69 |
Based on: 10-K (reporting date: 2023-12-31).
1 Click competitor name to see calculations.
If the company EV/EBITDA is lower then the EV/EBITDA of benchmark then company is relatively undervalued.
Otherwise, if the company EV/EBITDA is higher then the EV/EBITDA of benchmark then company is relatively overvalued.
Enterprise Value to EBITDA Ratio, Historical
| Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | ||
|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | ||||||
| Enterprise value (EV)1 | 88,543) | 83,977) | 96,445) | 82,629) | 73,350) | |
| Earnings before interest, tax, depreciation and amortization (EBITDA)2 | 3,666) | 3,342) | 3,160) | 2,668) | 2,436) | |
| Valuation Ratio | ||||||
| EV/EBITDA3 | 24.15 | 25.13 | 30.52 | 30.97 | 30.11 | |
| Benchmarks | ||||||
| EV/EBITDA, Competitors4 | ||||||
| AbbVie Inc. | 20.79 | 13.31 | 13.44 | — | — | |
| Amgen Inc. | 14.13 | 12.97 | 13.22 | — | — | |
| Bristol-Myers Squibb Co. | 6.51 | 9.46 | 8.65 | — | — | |
| Danaher Corp. | 26.41 | 18.42 | 21.05 | — | — | |
| Eli Lilly & Co. | 85.35 | 37.76 | 29.86 | — | — | |
| Gilead Sciences Inc. | 10.41 | 13.89 | 8.57 | — | — | |
| Johnson & Johnson | 16.45 | 14.78 | 14.47 | — | — | |
| Merck & Co. Inc. | 51.30 | 13.91 | 12.18 | — | — | |
| Pfizer Inc. | 22.50 | 6.12 | 8.64 | — | — | |
| Regeneron Pharmaceuticals Inc. | 20.16 | 15.27 | 6.68 | — | — | |
| Thermo Fisher Scientific Inc. | 21.83 | 20.25 | 20.21 | — | — | |
| Vertex Pharmaceuticals Inc. | 21.57 | 14.91 | 18.92 | — | — | |
| EV/EBITDA, Sector | ||||||
| Pharmaceuticals, Biotechnology & Life Sciences | 22.59 | 13.58 | 13.16 | — | — | |
| EV/EBITDA, Industry | ||||||
| Health Care | 20.27 | 14.00 | 14.33 | — | — | |
Based on: 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31).
3 2023 Calculation
EV/EBITDA = EV ÷ EBITDA
= 88,543 ÷ 3,666 = 24.15
4 Click competitor name to see calculations.
The financial trajectory from 2019 to 2023 reveals a steady increase in operational profitability contrasted with fluctuations in market valuation. A consistent upward trend in earnings before interest, tax, depreciation, and amortization indicates strong organic growth, while the Enterprise Value experienced a peak in 2021 followed by a correction and subsequent stabilization.
- EBITDA Growth Trends
- Earnings before interest, tax, depreciation, and amortization demonstrated uninterrupted annual growth over the five-year period. Starting at 2,436 million US dollars in 2019, the figure increased steadily each year to reach 3,666 million US dollars by December 31, 2023, reflecting a sustained expansion in core operational profitability.
- Enterprise Value Volatility
- Enterprise Value exhibited significant volatility compared to earnings. A growth phase was observed from 2019 through 2021, where the value rose from 73,350 million US dollars to a peak of 96,445 million US dollars. A subsequent contraction occurred in 2022, with the value falling to 83,977 million US dollars, before slightly recovering to 88,543 million US dollars in 2023.
- EV/EBITDA Multiple Compression
- The EV/EBITDA ratio remained stable between 2019 and 2021, fluctuating narrowly around the 30x mark. However, a distinct downward trend emerged in the latter two years of the period. The ratio declined to 25.13 in 2022 and further to 24.15 in 2023. This compression indicates that while absolute earnings continued to grow, the market valuation multiple decreased, resulting in a lower valuation relative to operational performance.
AI Ask an analyst for more
Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.
How can I help you?